April 2020
Volume 33, No. 4 |
|
|
|
|
|
|
Notice to BioPharm International subscribers currently receiving printed copies of the magazine:
Many readers working remotely may not have access to the print versions of BioPharm International; therefore, for upcoming issues, we will deliver the digital version of the magazine to you via email. Your print issues will continue to be delivered to you via postal mail and will be awaiting your return to the office. If you wish to change your delivery address, or delivery preference, you can do so via our online subscription form.
http://mmhpubs.mmhgroup.com/Welcome.aspx?pubid=BIOP
|
| |
| COVER STORY |
Cynthia A. Challener
Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.
read more
| UPSTREAM PROCESSING |
Agnes Shanley
New bioreactor designs, coupled with better media, process intensification and analytics, continue to improve upstream bioprocessing.
read more
| DOWNSTREAM PROCESSING |
Lauren Lavelle
The latest advances in downstream technologies include a fluid chromatography system, sensing and control units for hygienic valves, a compact valve platform, a membrane purification column, and a protein A affinity chromatography resin.
read more
|
|
|
| BioPharm International April Issue
|
|
| MANUFACTURING |
Felicity Thomas
Single-use solutions continue to grow in popularity, largely as a result of the cost and time efficiencies they can afford biopharma companies.
read more
|
ADVERTISEMENT
Featured Resources from BioPharm International
View our online resource center, sponsored by GE Healthcare, to explore a case study and articles on gaining and retaining skilled labor, modular bioprocessing, the good and bad of biosilimiars, and more.
 Learn More ››
| ANALYTICS |
Felicity Thomas
A variety of assays should be used to detect bacterial, fungal, and viral contaminants in the human source cells used for cell therapies.
read more
|
| QUALITY/REGULATIONS |
Feliza Mirasol
Demonstrating interchangeability can ensure biosimilar substitutability at the pharmacy level.
read more
| OPERATIONS |
Susan Haigney
Risk assessments, audits, and good communication between sponsor and supplier are key elements of supplier oversight.
read more
Hallie Forcinio
More sustainable and functional packaging protects temperature-sensitive drugs.
read more
Felicity Thomas
As a result of the rising use and development of biological drugs, the biopharma industry is witnessing an increase in the adoption of prefilled syringes.
read more
| OUTSOURCING |
Cynthia A. Challener
Experience, communication, collaboration, transparency, planning, and prioritization contribute to success.
read more
| BIOBUSINESS |
Agnes Shanley, Lauren Lavelle
As politicians focus on drug cost reduction, biopharmaceutical companies in the US are moving to states with lower taxes and relocating some facilities that had been offshore.
read more
|
|
|
|
| FROM THE EDITOR |
Rita C. Peters
As the coronavirus pandemic unfolds, the bio/pharma industry must practice science over hype.
read more
| REGULATORY BEAT |
Jill Wechsler
FDA is encouraging alternative insulins and challenging anticompetitive practices.
read more
| ASK THE EXPERT |
Susan J. Schniepp
N Addressing data integrity, quality culture, aging facilities, investigations/corrective actions and preventive actions, and risk management is key when conducting audits, says Susan J. Schniepp, executive vice-president of post-approval pharma and distinguished fellow, Regulatory Compliance Associates.
read more
|
|
| EVENTS |
June 8–12, 2020
June 22–24, 2020
July 15–17, 2020
more events
|
|
|
|
|
|
|
